NeuroBo Pharmaceuticals (NASDAQ:NRBO) Coverage Initiated at Maxim Group

Stock analysts at Maxim Group initiated coverage on shares of NeuroBo Pharmaceuticals (NASDAQ:NRBO) in a research note issued to investors on Wednesday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 150.31% from the stock’s previous close.

NeuroBo Pharmaceuticals Price Performance

NRBO opened at $4.00 on Wednesday. The company’s 50 day simple moving average is $4.15 and its 200-day simple moving average is $3.97. NeuroBo Pharmaceuticals has a one year low of $2.89 and a one year high of $6.75.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.